Pharmacy benefit managers last month reported an easing of demand for the antimalarial drug hydroxychloroquine following a rapid surge spurred by comments by the White House, Specialty Pharmacy Continuum reports.
The Trump administration had in the past suggested the drug was an effective treatment for COVID-19.
According to the report, Prime Therapeutics reported a sharp spike between March 17-25.
“During this time, we did receive a few escalated member inquiries regarding drug supply issues,” Prime Chief Clinical Officer David Lassen said. “This was primarily due to local/regional supply chain inventory adjustments. We assisted these members by redirecting to pharmacies with known inventory. We also took measures to limit quantities of prescriptions for new COVID-19 users to prevent further drug shortage concerns and/or potential stockpiling.”
To read the full report on Specialty Pharmacy Continuum, click here.